Rewriting Autoimmunity. One Serendipitous Discovery at a Time.

Pioneering a New Era in Autoimmune Therapeutics - Intervening Earlier and More Precisely in Immune Activation

Meeting the Urgent Need for Better Autoimmune Therapies

Autoimmune diseases affect over 5–10% of the global population and are on the rise. Conditions like rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis not only reduce quality of life but also lead to long-term disability, lost productivity, and increased healthcare costs. In many cases, patients face a lifetime of treatments that are broad, non-specific, and immunosuppressive, increasing their risk of infections, cancer, and other complications. 

Despite years of research, the need for safer, more effective therapies remains unmet. Most current drugs fail to provide durable control or true remission.

At Serendo Therapeutics, we’re advancing a new class of targeted therapies that act where autoimmunity begins — in the dysregulation of T and B cells. By precisely modulating these key immune cells, we aim to stop disease at its source without weakening the body’s natural defenses.

Targeting the Root of Autoimmunity: EA2 and Immune Modulation

At Serendo Therapeutics, we're developing a novel therapy that tackles autoimmune disease at its source: overactive T and B cells. Our lead target, Endophilin A2 (EA2), encoded by SH3GL1, plays a key role in immune cell receptor signaling.

We discovered that EA2 acts as a gatekeeper, regulating whether immune cells activate or stay tolerant. In autoimmune disease, this control fails. Our Nature Communications study shows that inhibiting EA2 can halt disease progression in preclinical models for autoimmunity—without compromising immunity against infections or cancer.

By targeting EA2, we offer precise immune modulation without broad immunosuppression.

Reference: Norin et al., Nat Commun 12, 610 (2021). https://doi.org/10.1038/s41467-020-20586-2

About Us

Serendo Therapeutics is a science-driven biotechnology company pioneering precision immunotherapies for autoimmune diseases. Our foundation lies in a moment of true serendipity — the unexpected discovery of Endophilin A2 (EA2) as a key regulator of adaptive immunity and immune tolerance.

What began as a genetic anomaly in a rodent model became a paradigm-shifting insight: by modulating EA2, we can prevent harmful autoimmune responses without suppressing the immune system entirely.

At Serendo, we translate this discovery into action. Our team of immunologists, translational scientists, medicinal chemists, and biotech entrepreneurs is building a pipeline of first-in-class therapies targeting EA2.
Bank Cards A line styled icon from Orion Icon Library.

Innovative Science

Harnessing cutting-edge research to pioneer new treatment pathways.
Like Hand A line styled icon from Orion Icon Library.

Precision Therapies

Targeting Endophilin A2 for effective immune modulation.
Wall Clock A line styled icon from Orion Icon Library.

Expert Team

Led by a seasoned leader and supported by world-class advisors in immunology, medicinal chemistry, and biotech innovation

Contact Us

Reach out for inquiries or collaboration opportunities.

ulrika.norin@serendotx.com

Join Us in Redefining Autoimmune Therapeutics

Subscribe to our LinkedIn page to receive updates on our precision therapies targeting Endophilin A2 (EA2) and be the first to know about our groundbreaking advancements in autoimmune treatment.